Tend Appoints Mike Goonewardene As New CEO
Gut Microbiome startup brings on Medical Device executive to lead the company to commercialization of CAP Device
Seattle, May 19, 2022 – Tend announced today that Mike Goonewardene has been appointed the new CEO of the company. An experienced leader in the healthcare market, Goonewardene will succeed Roslyn Hendriks. After serving as the company’s founding CEO, Hendriks is returning to her native Australia and will continue to support Tend as an advisor.
Mike Goonewardene has 30 years’ experience in medical device design, development, manufacturing, and commercialization, raising capital, and selling into the US healthcare markets. Most recently serving as the Chief Commercial Officer for Sterifre Medical, Mike also brings to Tend international market know-how and relationship-building experience.
“Mike’s background is highly aligned with Tend’s technology and market,” said Tend Board member Susan Preston of Sea Change Fund. “In addition to his long experience in healthcare and medical devices, he really understands the parameters impacting a young company’s potential success. That combination will make a great addition to the Tend team.”
In addition to his company leadership posts Mike serves on the Board of Directors of Kitsap Credit Union. He holds an MBA from Pepperdine University, a BS in Marketing from Indiana University and served as a Company Commander, U.S. Army, Infantry (Reserve).
ABOUT TEND
Launched in 2020, Tend Health Inc. (Tend) is a private company with a mission to improve the understanding of and access to the incredible healing power of the gut microbiome. The Tend Gut Microbiome Collection and Prep (CAP) device - designed, developed, and manufactured by the company - collects, mixes, filters, and encapsulates a stool sample for therapeutic use. Its patent-pending design improves current preparation, making it easier to offer a less invasive and more affordable treatment for patients. Tend also offers a comprehensive microbiome testing and analysis solution, designed to offer clinicians and patients a more meaningful understanding of the gut microbiome.